Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Details

Connection

Michael Bristow to Myocardial Contraction

This is a "connection" page, showing publications Michael Bristow has written about Myocardial Contraction.

 
Connection Strength
  
 
 
1.592
  
  1. Sucharov CC, Nakano SJ, Slavov D, Schwisow JA, Rodriguez E, Nunley K, Medway A, Stafford N, Nelson P, McKinsey TA, Movsesian M, Minobe W, Carroll IA, Taylor MRG, Bristow MR. A PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Myocardium. J Am Coll Cardiol. 2019 03 19; 73(10):1173-1184.
    View in: PubMed
    Score: 0.142
  2. Bristow MR. Contractile reserve and the response to cardiac resynchronization therapy. Int J Cardiol. 2018 02 01; 252:234-235.
    View in: PubMed
    Score: 0.132
  3. Bristow MR, Gilbert EM. Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J. 1995 Jul; 16 Suppl F:20-31.
    View in: PubMed
    Score: 0.110
  4. Port JD, Gilbert EM, Larrabee P, Mealey P, Volkman K, Ginsburg R, Hershberger RE, Murray J, Bristow MR. Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart. Circulation. 1990 Mar; 81(3):929-38.
    View in: PubMed
    Score: 0.076
  5. Feldman AM, Bristow MR. The beta-adrenergic pathway in the failing human heart: implications for inotropic therapy. Cardiology. 1990; 77 Suppl 1:1-32.
    View in: PubMed
    Score: 0.075
  6. Shaddy RE, Mak C, Bristow MR. Comparative in vitro myocardial inotropic effects and in vivo hemodynamic effects of forskolin and isoproterenol in young lambs. Pediatr Res. 1989 Jun; 25(6):580-4.
    View in: PubMed
    Score: 0.072
  7. Anderson FL, Kralios AC, Hershberger R, Bristow MR. Effect of vasoactive intestinal peptide on myocardial contractility and coronary blood flow in the dog: comparison with isoproterenol and forskolin. J Cardiovasc Pharmacol. 1988 Sep; 12(3):365-71.
    View in: PubMed
    Score: 0.069
  8. Lowes BD, Zolty R, Shakar SF, Brieke A, Gray N, Reed M, Calalb M, Minobe W, Lindenfeld J, Wolfel EE, Geraci M, Bristow MR, Cleveland J. Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers. J Heart Lung Transplant. 2007 Nov; 26(11):1170-6.
    View in: PubMed
    Score: 0.065
  9. Feldman AM, Oren RM, Abraham WT, Boehmer JP, Carson PE, Eichhorn E, Gilbert EM, Kao A, Leier CV, Lowes BD, Mathier MA, McGrew FA, Metra M, Zisman LS, Shakar SF, Krueger SK, Robertson AD, White BG, Gerber MJ, Wold GE, Bristow MR. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial. Am Heart J. 2007 Nov; 154(5):861-9.
    View in: PubMed
    Score: 0.064
  10. Bristow MR, Ginsburg R, Gilbert EM, Hershberger RE. Heterogeneous regulatory changes in cell surface membrane receptors coupled to a positive inotropic response in the failing human heart. Basic Res Cardiol. 1987; 82 Suppl 2:369-76.
    View in: PubMed
    Score: 0.061
  11. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986 Sep; 59(3):297-309.
    View in: PubMed
    Score: 0.060
  12. Bristow MR. Cardiac resynchronization therapy and adrenergic mechanisms. Am J Physiol Heart Circ Physiol. 2006 Dec; 291(6):H2590-1.
    View in: PubMed
    Score: 0.059
  13. Xu Y, Lu L, Greyson C, Rizeq M, Nunley K, Wyatt B, Bristow MR, Long CS, Schwartz GG. The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol. 2006 May; 290(5):H1798-807.
    View in: PubMed
    Score: 0.057
  14. Bristow MR, Ginsburg R, Strosberg A, Montgomery W, Minobe W. Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest. 1984 Jul; 74(1):212-23.
    View in: PubMed
    Score: 0.051
  15. Ginsburg R, Esserman LJ, Bristow MR. Myocardial performance and extracellular ionized calcium in a severely failing human heart. Ann Intern Med. 1983 May; 98(5 Pt 1):603-6.
    View in: PubMed
    Score: 0.047
  16. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982 Jul 22; 307(4):205-11.
    View in: PubMed
    Score: 0.045
  17. Bristow MR, Shakar SF, Linseman JV, Lowes BD. Inotropes and beta-blockers: is there a need for new guidelines? J Card Fail. 2001 Jun; 7(2 Suppl 1):8-12.
    View in: PubMed
    Score: 0.041
  18. Bristow M. Of phospholamban, mice, and humans with heart failure. Circulation. 2001 Feb 13; 103(6):787-8.
    View in: PubMed
    Score: 0.041
  19. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000 Nov 14; 102(20 Suppl 4):IV14-23.
    View in: PubMed
    Score: 0.040
  20. Bristow MR, Schwartz HD, Binetti G, Harrison DC, Daniels JR. Ionized calcium and the heart. Elucidation of in vivo concentration-response relationships in the open-chest dog. Circ Res. 1977 Oct; 41(4):565-74.
    View in: PubMed
    Score: 0.032
  21. Focaccio A, Peeters G, Movsesian M, Roden R, Eki Y, Krall J, Bristow MR. Mechanism of action of OPC-8490 in human ventricular myocardium. Circulation. 1996 Feb 15; 93(4):817-25.
    View in: PubMed
    Score: 0.029
  22. Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, Bristow MR. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995 Dec; 108(6):1524-32.
    View in: PubMed
    Score: 0.028
  23. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992 Mar; 89(3):803-15.
    View in: PubMed
    Score: 0.022
  24. O'Connell JB, Gilbert EM, Renlund DG, Bristow MR. Enoximone as a bridge to heart transplantation: the Utah experience. J Heart Lung Transplant. 1991 May-Jun; 10(3):477-81.
    View in: PubMed
    Score: 0.021
  25. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 1990 Aug; 82(2 Suppl):I12-25.
    View in: PubMed
    Score: 0.020
  26. Hershberger RE, Anderson FL, Bristow MR. Vasoactive intestinal peptide receptor in failing human ventricular myocardium exhibits increased affinity and decreased density. Circ Res. 1989 Aug; 65(2):283-94.
    View in: PubMed
    Score: 0.018
  27. Bristow MR. The beta-adrenergic receptor. Configuration, regulation, mechanism of action. Postgrad Med. 1988 Feb 29; Spec No:19-26.
    View in: PubMed
    Score: 0.017
  28. Bristow MR, Ginsburg R. Beta 2 receptors on myocardial cells in human ventricular myocardium. Am J Cardiol. 1986 Apr 25; 57(12):3F-6F.
    View in: PubMed
    Score: 0.015
  29. Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. Beta-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol. 1985 Jul; 17 Suppl 2:41-52.
    View in: PubMed
    Score: 0.014
  30. Fowler MB, Bristow MR. Rationale for beta-adrenergic blocking drugs in cardiomyopathy. Am J Cardiol. 1985 Apr 26; 55(10):120D-124D.
    View in: PubMed
    Score: 0.014
  31. Bristow MR. Myocardial beta-adrenergic receptor downregulation in heart failure. Int J Cardiol. 1984 May; 5(5):648-52.
    View in: PubMed
    Score: 0.013
  32. Ginsburg R, Bristow MR, Billingham ME, Stinson EB, Schroeder JS, Harrison DC. Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J. 1983 Sep; 106(3):535-40.
    View in: PubMed
    Score: 0.012
  33. Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000 Jun; 6(2):115-9.
    View in: PubMed
    Score: 0.010
  34. Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol. 1999 Apr 15; 83(8):1201-5.
    View in: PubMed
    Score: 0.009
  35. Deisher TA, Narita H, Zera P, Ginsburg R, Bristow MR, Billingham ME, Fowler MB, Hoffman BB. Protective effect of clentiazem against epinephrine-induced cardiac injury in rats. J Pharmacol Exp Ther. 1993 Jul; 266(1):262-9.
    View in: PubMed
    Score: 0.006
  36. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989 Mar; 79(3):483-90.
    View in: PubMed
    Score: 0.004
  37. Ginsburg R, Bristow MR, Stinson EB, Harrison DC. Histamine receptors in the human heart. Life Sci. 1980 Jun 30; 26(26):2245-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)